NCT05371145 Carnosine for Peripheral Arterial Disease Patients
| NCT ID | NCT05371145 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Shahid Baba |
| Condition | Peripheral Arterial Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2024-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2023-03-01 with a primary completion date of 2024-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.
Eligibility Criteria
Inclusion Criteria: 1. Male subjects more than \>50 to \<80 years of age. 2. White or African American race. 3. English Speaking. 4. ABI 0.4-\< 0.60 5. Willing to comply with protocol requirements. 6. Able to provide informed consent. - Exclusion Criteria: 1. Subjects with HIV, hepatitis, significant liver disease, active infection, anemia, organ transplant, renal disease requiring dialysis, lung disease requiring oxygen, significant congenital heart disease, cancer of any type, and untreated thyroid disease. 2. Diagnosis of carnosinemia. 3. Known allergy to L-carnosine or meat. 4. Presence of a pacemaker. 5. Obesity from a known genetic defect. 6. Dementia. 7. Critical limb ischemia with below or above knee amputations. 8. Foot ulcers. 9. Major amputations. 10. Participating in other clinical trials. 11. End stage renal disease. 12. Presence of significant injury within 30 days before enrollment. 13. Prisoners. 14. Any metallic implants. 15. Poorly controlled diabetes (HbA1C \>9%) -
Frequently Asked Questions
Who can join the NCT05371145 clinical trial?
This trial is open to male participants only, aged 50 Years or older, up to 80 Years, studying Peripheral Arterial Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05371145 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05371145 currently recruiting?
Yes, NCT05371145 is actively recruiting participants. Visit ClinicalTrials.gov or contact Shahid Baba to inquire about joining.
Where is the NCT05371145 trial being conducted?
This trial is being conducted at Louisville, United States.
Who is sponsoring the NCT05371145 clinical trial?
NCT05371145 is sponsored by Shahid Baba. The trial plans to enroll 20 participants.